NCT06308952 Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
| NCT ID | NCT06308952 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Duan Chuanzhi |
| Condition | Cerebrovascular Event |
| Study Type | INTERVENTIONAL |
| Enrollment | 354 participants |
| Start Date | 2024-07-30 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 354 participants in total. It began in 2024-07-30 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
APICES trial is an investigator-initiated, multicenter, multicenter, randomized, double-blind, placebo-controlled clinical trial that plans to enroll 396 patients with a 1-year follow-up, including a neurovascular imaging examination \[digital subtraction angiography (DSA), CT angiography (CTA) or magnetic resonance angiography (MRA)\] at 6 months after index treatment. It was designed in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study was approved by the Ethics Committee of Zhujiang Hospital of South Medical University (2024-KY-032-02) and registered at ClinicalTrials.gov (NCT06308952). The participants will be recruited from twelve advanced stroke centers in China.
Eligibility Criteria
Inclusion criteria: 1. Aged 18 to 75 years old, male or non-pregnant female; 2. UIA diagnosed by CTA, MRA, or DSA; 3. Maximal aneurysmal diameter between 3 and 25mm; 4. Understands the nature of the procedure and provision of written informed consent; 5. Indications for FD implantation with or without adjunctive coiling; 6. Is willing to return to the investigational site for follow-up according to our protocol. Exclusion criteria: Patients will be excluded if they meet any of the following criteria: 1. Contraindications to atorvastatin treatment or known allergy to atorvastatin; 2. Pregnancy or lactation; 3. Presence of other vascular lesions (coronary artery disease, abdominal aortic aneurysm, intracranial atherosclerotic stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.); 4. Prolonged statin therapy (≥30 days) or prior indications for atorvastatin therapy according to the Chinese guidelines for lipid management (2023) 21; 5. Ruptured aneurysms or target aneurysm received previous operative or endovascular treatment; 6. Patient currently using drugs that interact with atorvastatin metabolism (including transporter inhibitors, cyclosporine, protease inhibitors, other lipid-lowering medications (such as fibrates, ezetimibe, pcsk9 inhibitor, etc.), antacids, erythromycin, cytochrome P450 enzyme, colchicine, etc.); 7. Patients diagnosed with multiple intracranial aneurysms who require treatment for two or more intracranial aneurysms within a one-year period; 8. The target aneurysm is non-saccular (dissecting, fusiform, pseudo, infectious, etc.) 9. Other situations that the researcher deems unsuitable for inclusion in the study (inability to receive anti-platelet or anticoagulant medication; allergy or contraindication for the use of FD alloy, history of life-threatening allergy to contrast dye, ect). 10. Patient was determined that intravenous general anesthesia or general anesthesia with tracheal intubation could not be tolerated. 11. Unwilling to be followed up or likely to have poor treatment compliance at initial screening; 12. Life expectancy less than 3 years; 13. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4); 14. Enrollment in another trial. Withdrawal criteria In this trial, participants who have provided written informed consent but are unable to complete the entire study for any reason will be withdrawn. These circumstances include the following: 1. The participants voluntarily quit the trial for various reasons; 2. Occurrence of serious adverse events (SAEs). The study may be terminated by the participants, principal investigators, ethics committee, sponsor, or regulatory authorities based on ethical considerations; 3. Early termination of the process based on the investigator's judgment in order to prevent development of severe complications; 4. Significant deviation in implementation, or the subject failed to comply with the scheduled protocol; 5. Miss the follow-up due to changes in working/living places, or fortuitous accident (traffic accident, bone fracture, accidental death, ect.). Thus, close follow-up should be conducted to determine their relationship with the usage of FD and experimental drug; 6. Flawed or absence of informed consents.
Contact & Investigator
Chuanzhi Duan, MD
STUDY DIRECTOR
Southern Medical University, China
Frequently Asked Questions
Who can join the NCT06308952 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cerebrovascular Event. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06308952 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06308952 currently recruiting?
Yes, NCT06308952 is actively recruiting participants. Contact the research team at doctor_duanzj@163.com for enrollment information.
Where is the NCT06308952 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06308952 clinical trial?
NCT06308952 is sponsored by Duan Chuanzhi. The principal investigator is Chuanzhi Duan, MD at Southern Medical University, China. The trial plans to enroll 354 participants.